Skip to main content
. 2018 Aug 24;32(12):1173–1181. doi: 10.1007/s40263-018-0553-1

Fig. 3.

Fig. 3

Proportions of patients with and without prior DMT use achieving a clinically significant change in cognition score from baseline to 1 year (a, b) and to 2 years (c, d) of natalizumab treatment. All p values for between-group comparisons were ≥ 0.05. *CI is not shown. GCS global cognitive score, DMT disease-modifying therapy, CI confidence interval